Logo

QuantuMDx: Jonathan O'Halloran, Neil Butler, Elaine Warburton, John Burn

Jan 27, 2020

QuantuMDx announced the appointments of Jonathan O'Halloran as CEO and Neil Butler as chairman of the board as the company begins its transition to commercialization.

A cofounder and former CSO of the firm, O'Halloran invented many of its proprietary technologies. He has a background in genetics and genomics and has been focusing on tuberculosis and antimicrobial resistance for the past 12 years.

QuantuMDx appointed Neil Butler to its board as a non-executive director in July 2019. He also serves on the boards of Nidor Dx, Radisens, and Spectromics and previously served as chair and non-executive director for Binx Health and Genomic Vision.

QuantuMDx said its CEO and Cofounder Elaine Warburton will move into the role of non-executive director and continue to support QuantuMDx in an ambassadorial role, including with key strategic projects. John Burn will step back as chairman, a role he had undertaken upon the company's inception in 2008, and become vice-chairman of the board of directors.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.